FDA Oks Genentech's Tecentriq Hybreza As First & Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
13/9 02:56
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said Thursday that the U.S. Food and Drug Administration has approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for pati...